VEGFA and renal cell carcinoma: As therapy, we chose bevacizumab, a humanized anti-Vascular Endothelial Growth Factor (VEGF) monoclonal antibody that selectively binds circulating human VEGF and thus inhibits its binding to cell surface receptors on blood vessels 44, used in RCC therapy, including first line therapies.